Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 150 entries
Sorted by: Best Match Show Resources per page
Nonlinearity measurements of solar cells with an LED-based combinatorial flux addition method.

Metrologia

Hamadani BH, Shore A, Roller J, Yoon HW, Campanelli M.
PMID: 27524837
Metrologia. 2016 Feb;53(1):76-85. doi: 10.1088/0026-1394/53/1/76. Epub 2016 Jan 13.

We present a light emitting diode (LED)-based system utilizing a combinatorial flux addition method to investigate the nonlinear relationship in solar cells between the output current of the cell and the incident irradiance level. The magnitude of the light...

Cite
Hamadani BH, Shore A, Roller J, et al. Nonlinearity measurements of solar cells with an LED-based combinatorial flux addition method. Metrologia. 2016;53(1):76-85doi: 10.1088/0026-1394/53/1/76.
Hamadani, B. H., Shore, A., Roller, J., Yoon, H. W., & Campanelli, M. (2016). Nonlinearity measurements of solar cells with an LED-based combinatorial flux addition method. Metrologia, 53(1), 76-85. https://doi.org/10.1088/0026-1394/53/1/76
Hamadani, Behrang H, et al. "Nonlinearity measurements of solar cells with an LED-based combinatorial flux addition method." Metrologia vol. 53,1 (2016): 76-85. doi: https://doi.org/10.1088/0026-1394/53/1/76
Hamadani BH, Shore A, Roller J, Yoon HW, Campanelli M. Nonlinearity measurements of solar cells with an LED-based combinatorial flux addition method. Metrologia. 2016 Feb;53(1):76-85. doi: 10.1088/0026-1394/53/1/76. Epub 2016 Jan 13. PMID: 27524837; PMCID: PMC4977582.
Copy Download .nbib Format: NLM
In Reply to Samaratunga et al.

International journal of radiation oncology, biology, physics

Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J.
PMID: 27869088
Int J Radiat Oncol Biol Phys. 2016 Dec 01;96(5):1127-1128. doi: 10.1016/j.ijrobp.2016.08.027.

No abstract available.

Cite
Zietman A, Smith J, Klein E, et al. In Reply to Samaratunga et al. Int J Radiat Oncol Biol Phys. 2016;96(5):1127-1128doi: 10.1016/j.ijrobp.2016.08.027.
Zietman, A., Smith, J., Klein, E., Droller, M., Dasgupta, P., & Catto, J. (2016). In Reply to Samaratunga et al. International journal of radiation oncology, biology, physics, 96(5), 1127-1128. https://doi.org/10.1016/j.ijrobp.2016.08.027
Zietman, Anthony, et al. "In Reply to Samaratunga et al." International journal of radiation oncology, biology, physics vol. 96,5 (2016): 1127-1128. doi: https://doi.org/10.1016/j.ijrobp.2016.08.027
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. In Reply to Samaratunga et al. Int J Radiat Oncol Biol Phys. 2016 Dec 01;96(5):1127-1128. doi: 10.1016/j.ijrobp.2016.08.027. PMID: 27869088.
Copy Download .nbib Format: NLM
Patents and literature.

Applied biochemistry and biotechnology

Kit M, Narasimhan MJ, Anderson JA, Zimmermann U, Pilwat G, Furuya T, Tani Y, Kolehmainen SE, Tarkkanen V, Barrett SP, Gestrelius SM, Belloc A, Florent J, Lunel J, Palla J, Mancy D, Bailey JE, Cho YK, Mouri T, Kayama H, Foley SE, Oriel PJ, Epstein CC, Kimura K, Spraker PW, Ljungdahl LG, Wieget JK, Levine DW, Thilly WG, Wang DI, Wong JS, Eisinger MG, Young FE, Wilson GA, Mottice SL, Green H, Kehinde O, Buhler M, Olofsson M, Osseux PF, Degen L, Branduzzi P, Olivieri R, Cimini N, Kang KS, Veeder GT, Latymer Z, Andersen G, Drobot W, Monsheimer R, Pfleiderer E, Hidaka H, Kohno T, Eida T, Weisrock WP, Stevens VC, Takezawa K, Hiratani H, Wandrey C, Wichmann R, Leuchtenberger W, Kula M, Buckmann A, Troller J, Koshugi J, Frommer W, Muller L, Schmidt D, Puls W, Krause H, Heber U, Cohen SN, Wahl GM, Stark GR, Collins J, Hohn B, Sugano H, Matsui Y.
PMID: 24234232
Appl Biochem Biotechnol. 1982 May;7(3):217-30. doi: 10.1007/BF02798299.

No abstract available.

Cite
Kit M, Narasimhan MJ, Anderson JA, et al. Patents and literature. Appl Biochem Biotechnol. 1982;7(3):217-30doi: 10.1007/BF02798299.
Kit, M., Narasimhan, M. J., Anderson, J. A., Zimmermann, U., Pilwat, G., Furuya, T., Tani, Y., Kolehmainen, S. E., Tarkkanen, V., Barrett, S. P., Gestrelius, S. M., Belloc, A., Florent, J., Lunel, J., Palla, J., Mancy, D., Bailey, J. E., Cho, Y. K., Mouri, T., Kayama, H., Foley, S. E., Oriel, P. J., Epstein, C. C., Kimura, K., Spraker, P. W., Ljungdahl, L. G., Wieget, J. K., Levine, D. W., Thilly, W. G., Wang, D. I., Wong, J. S., Eisinger, M. G., Young, F. E., Wilson, G. A., Mottice, S. L., Green, H., Kehinde, O., Buhler, M., Olofsson, M., Osseux, P. F., Degen, L., Branduzzi, P., Olivieri, R., Cimini, N., Kang, K. S., Veeder, G. T., Latymer, Z., Andersen, G., Drobot, W., Monsheimer, R., Pfleiderer, E., Hidaka, H., Kohno, T., Eida, T., Weisrock, W. P., Stevens, V. C., Takezawa, K., Hiratani, H., Wandrey, C., Wichmann, R., Leuchtenberger, W., Kula, M., Buckmann, A., Troller, J., Koshugi, J., Frommer, W., Muller, L., Schmidt, D., Puls, W., Krause, H., Heber, U., Cohen, S. N., Wahl, G. M., Stark, G. R., Collins, J., Hohn, B., Sugano, H., & Matsui, Y. (1982). Patents and literature. Applied biochemistry and biotechnology, 7(3), 217-30. https://doi.org/10.1007/BF02798299
Kit, M, et al. "Patents and literature." Applied biochemistry and biotechnology vol. 7,3 (1982): 217-30. doi: https://doi.org/10.1007/BF02798299
Kit M, Narasimhan MJ, Anderson JA, Zimmermann U, Pilwat G, Furuya T, Tani Y, Kolehmainen SE, Tarkkanen V, Barrett SP, Gestrelius SM, Belloc A, Florent J, Lunel J, Palla J, Mancy D, Bailey JE, Cho YK, Mouri T, Kayama H, Foley SE, Oriel PJ, Epstein CC, Kimura K, Spraker PW, Ljungdahl LG, Wieget JK, Levine DW, Thilly WG, Wang DI, Wong JS, Eisinger MG, Young FE, Wilson GA, Mottice SL, Green H, Kehinde O, Buhler M, Olofsson M, Osseux PF, Degen L, Branduzzi P, Olivieri R, Cimini N, Kang KS, Veeder GT, Latymer Z, Andersen G, Drobot W, Monsheimer R, Pfleiderer E, Hidaka H, Kohno T, Eida T, Weisrock WP, Stevens VC, Takezawa K, Hiratani H, Wandrey C, Wichmann R, Leuchtenberger W, Kula M, Buckmann A, Troller J, Koshugi J, Frommer W, Muller L, Schmidt D, Puls W, Krause H, Heber U, Cohen SN, Wahl GM, Stark GR, Collins J, Hohn B, Sugano H, Matsui Y. Patents and literature. Appl Biochem Biotechnol. 1982 May;7(3):217-30. doi: 10.1007/BF02798299. PMID: 24234232.
Copy Download .nbib Format: NLM
Reinventing the Contingency Wheel: Scalable Visual Analytics of Large Categorical Data.

IEEE transactions on visualization and computer graphics

Alsallakh B, Aigner W, Miksch S, Groller ME.
PMID: 26357194
IEEE Trans Vis Comput Graph. 2012 Dec;18(12):2849-58. doi: 10.1109/TVCG.2012.254.

Contingency tables summarize the relations between categorical variables and arise in both scientific and business domains. Asymmetrically large two-way contingency tables pose a problem for common visualization methods. The Contingency Wheel has been recently proposed as an interactive visual...

Cite
Alsallakh B, Aigner W, Miksch S, et al. Reinventing the Contingency Wheel: Scalable Visual Analytics of Large Categorical Data. IEEE Trans Vis Comput Graph. 2012;18(12):2849-58doi: 10.1109/TVCG.2012.254.
Alsallakh, B., Aigner, W., Miksch, S., & Groller, M. E. (2012). Reinventing the Contingency Wheel: Scalable Visual Analytics of Large Categorical Data. IEEE transactions on visualization and computer graphics, 18(12), 2849-58. https://doi.org/10.1109/TVCG.2012.254
Alsallakh, B, et al. "Reinventing the Contingency Wheel: Scalable Visual Analytics of Large Categorical Data." IEEE transactions on visualization and computer graphics vol. 18,12 (2012): 2849-58. doi: https://doi.org/10.1109/TVCG.2012.254
Alsallakh B, Aigner W, Miksch S, Groller ME. Reinventing the Contingency Wheel: Scalable Visual Analytics of Large Categorical Data. IEEE Trans Vis Comput Graph. 2012 Dec;18(12):2849-58. doi: 10.1109/TVCG.2012.254. PMID: 26357194.
Copy Download .nbib Format: NLM
Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder.

The Journal of urology

Droller MJ.
PMID: 12136827
J Urol. 2002 Aug;168(2):857-8.

No abstract available.

Cite
Droller MJ. Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. J Urol. 2002;168(2):857-8
Droller, M. J. (2002). Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. The Journal of urology, 168(2), 857-8.
Droller, Michael J. "Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder." The Journal of urology vol. 168,2 (2002): 857-8.
Droller MJ. Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. J Urol. 2002 Aug;168(2):857-8. PMID: 12136827.
Copy Download .nbib Format: NLM
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.

The Journal of urology

Droller D.
PMID: 12402837
J Urol. 2002 Nov;168(5):2306-7.

No abstract available.

Cite
Droller D. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. J Urol. 2002;168(5):2306-7
Droller, D. (2002). Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. The Journal of urology, 168(5), 2306-7.
Droller, Droller. "Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder." The Journal of urology vol. 168,5 (2002): 2306-7.
Droller D. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. J Urol. 2002 Nov;168(5):2306-7. PMID: 12402837.
Copy Download .nbib Format: NLM
Subsurface valleys and geoarcheology of the eastern sahara revealed by shuttle radar.

Science (New York, N.Y.)

McCauley JF, Schaber GG, Breed CS, Grolier MJ, Haynes CV, Issawi B, Elachi C, Blom R.
PMID: 17790589
Science. 1982 Dec 03;218(4576):1004-20. doi: 10.1126/science.218.4576.1004.

The shuttle imaging radar (SIR-A) carried on the space shuttle Columbia in November 1981 penetrated the extremely dry Selima Sand Sheet, dunes, and drift sand of the eastern Sahara, revealing previously unknown buried valleys, geologic structures, and possible Stone...

Cite
McCauley JF, Schaber GG, Breed CS, et al. Subsurface valleys and geoarcheology of the eastern sahara revealed by shuttle radar. Science. 1982;218(4576):1004-20doi: 10.1126/science.218.4576.1004.
McCauley, J. F., Schaber, G. G., Breed, C. S., Grolier, M. J., Haynes, C. V., Issawi, B., Elachi, C., & Blom, R. (1982). Subsurface valleys and geoarcheology of the eastern sahara revealed by shuttle radar. Science (New York, N.Y.), 218(4576), 1004-20. https://doi.org/10.1126/science.218.4576.1004
McCauley, J F, et al. "Subsurface valleys and geoarcheology of the eastern sahara revealed by shuttle radar." Science (New York, N.Y.) vol. 218,4576 (1982): 1004-20. doi: https://doi.org/10.1126/science.218.4576.1004
McCauley JF, Schaber GG, Breed CS, Grolier MJ, Haynes CV, Issawi B, Elachi C, Blom R. Subsurface valleys and geoarcheology of the eastern sahara revealed by shuttle radar. Science. 1982 Dec 03;218(4576):1004-20. doi: 10.1126/science.218.4576.1004. PMID: 17790589.
Copy Download .nbib Format: NLM
Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.

The Journal of urology

Droller MJ.
PMID: 14598843
J Urol. 2003 Aug;170(2):670-1.

No abstract available.

Cite
Droller MJ. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. J Urol. 2003;170(2):670-1
Droller, M. J. (2003). Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. The Journal of urology, 170(2), 670-1.
Droller, Michael J. "Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder." The Journal of urology vol. 170,2 (2003): 670-1.
Droller MJ. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. J Urol. 2003 Aug;170(2):670-1. PMID: 14598843.
Copy Download .nbib Format: NLM
Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.

The Journal of urology

Droller MJ.
PMID: 14598844
J Urol. 2003 Aug;170(2):671-2.

No abstract available.

Cite
Droller MJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. J Urol. 2003;170(2):671-2
Droller, M. J. (2003). Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. The Journal of urology, 170(2), 671-2.
Droller, Michael J. "Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices." The Journal of urology vol. 170,2 (2003): 671-2.
Droller MJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. J Urol. 2003 Aug;170(2):671-2. PMID: 14598844.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

European urology

Droller MJ.
PMID: 18061997
Eur Urol. 2006 Nov;50(5):1119-20. doi: 10.1016/j.eururo.2006.08.018.

No abstract available.

Cite
Droller MJ. Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Eur Urol. 2006;50(5):1119-20doi: 10.1016/j.eururo.2006.08.018.
Droller, M. J. (2006). Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. European urology, 50(5), 1119-20. https://doi.org/10.1016/j.eururo.2006.08.018
Droller, Michael J. "Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay." European urology vol. 50,5 (2006): 1119-20. doi: https://doi.org/10.1016/j.eururo.2006.08.018
Droller MJ. Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Eur Urol. 2006 Nov;50(5):1119-20. doi: 10.1016/j.eururo.2006.08.018. PMID: 18061997.
Copy Download .nbib Format: NLM
Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.

The Journal of urology

Droller MJ.
PMID: 14601564
J Urol. 2003 Aug;170(2):674-5.

No abstract available.

Cite
Droller MJ. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. J Urol. 2003;170(2):674-5
Droller, M. J. (2003). Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. The Journal of urology, 170(2), 674-5.
Droller, Michael J. "Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer." The Journal of urology vol. 170,2 (2003): 674-5.
Droller MJ. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. J Urol. 2003 Aug;170(2):674-5. PMID: 14601564.
Copy Download .nbib Format: NLM
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors.

Urologic oncology

Kirschenbaum A, Wang JP, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC.
PMID: 21227046
Urol Oncol. 1997 Jan-Feb;3(1):3-10. doi: 10.1016/s1078-1439(97)00001-x.

The LNCaP human prostate cancer cell line is androgenand stromal-dependent for in vivo growth. We co-inoculated LNCaP cells with human fetal fibroblasts, isolated from prostate, bone (male), and lung (male and female) derived from 18- to 22-week-old human fetal...

Cite
Kirschenbaum A, Wang JP, Ren M, et al. Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncol. 1997;3(1):3-10doi: 10.1016/s1078-1439(97)00001-x.
Kirschenbaum, A., Wang, J. P., Ren, M., Schiff, J. D., Aaronson, S. A., Droller, M. J., Ferrara, N., Holland, J. F., & Levine, A. C. (1997). Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urologic oncology, 3(1), 3-10. https://doi.org/10.1016/s1078-1439(97)00001-x
Kirschenbaum, A, et al. "Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors." Urologic oncology vol. 3,1 (1997): 3-10. doi: https://doi.org/10.1016/s1078-1439(97)00001-x
Kirschenbaum A, Wang JP, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC. Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncol. 1997 Jan-Feb;3(1):3-10. doi: 10.1016/s1078-1439(97)00001-x. PMID: 21227046.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 150 entries